What timing. On the first day of Life Science Tennessee’s annual conference – LSTCON, PitchBook published its latest report that focused on the biotech sector.
“In this analyst note, we discuss how the biotech company lifecycle differs from the tech company lifecycle and why the VC asset class is uniquely positioned to fund these risky companies,” the authors write. “We also provide a comparison between these two industries by looking at the following metrics: time since founding to first VC financing, time between rounds, and time since founding to IPO.”
Want more information? Here’s a link to the report.